Head, Department of Oncology
- Professor of Experimental Cancer Medicine
- Consultant Medical Oncologist, Oxford Cancer and Haematology Centre
My research concentrates on the development of new cancer drugs and on the treatment of melanoma.
Mark Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology, consultant Medical Oncologist at the Oxford Cancer and Haematology Centre and Head of the Department of Oncology at the University of Oxford.
Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Foundation Trust and Director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre.
He studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital. Mark is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group. He leads several clinical trials in the national portfolio.
Thomas A. et al, (2019), Eur J Cancer, 124, 131 - 141
Neurocognitive outcomes in a phase-3 randomised trial comparing adjuvant whole brain radiotherapy with observation after local treatment of brain metastases in patients with melanoma
Dhillon H. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 99 - 100
Phase-3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs)
Fogarty GB. et al, (2019), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 100 - 101
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber JS. et al, (2019), ANNALS OF ONCOLOGY, 30, 533 - +
Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma
Fairfax B. et al, (2019), ANNALS OF ONCOLOGY, 30